Expertise in
7
conditions

Gerald W. Prager

Vienna, AT 
Expertise in
7
conditions
Vienna, AT 
OverviewLocationsClinical Research

Overview

Gerald Prager practices in Vienna, Austria. Mr. Prager is highly rated in 7 conditions, according to our data. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Sleeve Gastrectomy, and Gastrectomy.

His clinical research consists of co-authoring 146 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Vienna, Austria
Other Locations
1090, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Dronabinol in the Improvement of ChemOthErapy-induced and Tumor-Related Symptoms in Patients With Locally Advanced or Metastatic Pancreatic Cancer During First-line Chemotherapy (DIsCOvER)
Enrollment Status: Completed
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drug: Dronabinol
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
Pilot Study: Biomarker Directed Treatment in Metastatic Colorectal Cancer
Pilot Study: Biomarker Directed Treatment in Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

146 Total Publications

Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Prager's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile